Ustün Hüseyin, Astarcı Hesna Müzeyyen, Altunkaya Canan, Yılmaz Sırma, Barın Ahmet, Ekici Serap, Caydere Muzaffer
Pathology Department, Ankara Training and Research Hospital, Ankara, Turkey.
Acta Cytol. 2012;56(4):361-9. doi: 10.1159/000338218. Epub 2012 Jul 25.
The goal of this study was to report an experience with thyroid fine-needle aspiration (FNA) cases that can be placed into National Cancer Institute-designated thyroid FNA diagnostic categories for follicular patterned lesions divided into three diagnostic categories: follicular lesion of undetermined significance/atypia of undetermined significance (AUS/FLUS), suspicious for follicular neoplasm (SFON), and suspicious for malignancy.
The study cohort included 4,284 cases for the period between January 2007 and July 2011 and all available follow-up data was obtained. All cases classified as 'atypical' and 'rule out follicular neoplasm' were included in the AUS/FLUS category (n = 3,903), whereas cases classified as 'suspicious for' or 'consistent with follicular or Hürthle cell neoplasm' (n = 381) were included in the SFON diagnostic category and compared with histopathologic follow-up.
During this period, 14,628 thyroid FNAs were reported in 12,238 patients. Repeat FNA (RFNA) was performed in 1,366/3,903 (35%) patients classified as AUS/FLUS. Histologic outcome data was available in 1,756/3,903 (45%) cases diagnosed as AUS/FLUS and 243/381 (64%) cases diagnosed as SFON. The rate of malignancy in AUS/FLUS cases with and without RFNA was 29 and 14% respectively, and it was 26% in SFON cases.
The current data shows that the malignancy rates differ between categories and AUS/FLUS cases are best managed by RFNA for selection of cases that can benefit from surgical excision.
本研究的目的是报告甲状腺细针穿刺抽吸(FNA)病例的经验,这些病例可被归入美国国立癌症研究所指定的甲状腺FNA诊断类别,用于滤泡型病变,分为三个诊断类别:意义未明的滤泡性病变/意义未明的非典型病变(AUS/FLUS)、可疑滤泡性肿瘤(SFON)和可疑恶性肿瘤。
研究队列包括2007年1月至2011年7月期间的4284例病例,并获取了所有可用的随访数据。所有分类为“非典型”和“排除滤泡性肿瘤”的病例被纳入AUS/FLUS类别(n = 3903),而分类为“可疑”或“符合滤泡或许特莱细胞肿瘤”的病例(n = 381)被纳入SFON诊断类别,并与组织病理学随访结果进行比较。
在此期间,12238例患者共进行了14628次甲状腺FNA。1366/3903(35%)例分类为AUS/FLUS的患者进行了重复FNA(RFNA)。1756/3903(45%)例诊断为AUS/FLUS的病例和243/381(64%)例诊断为SFON的病例有组织学结果数据。有RFNA和无RFNA的AUS/FLUS病例的恶性率分别为29%和14%,SFON病例的恶性率为26%。
目前的数据表明,不同类别之间的恶性率存在差异,对于AUS/FLUS病例,通过RFNA来选择可从手术切除中获益的病例是最佳处理方式。